@asnpublications Tag

20 Oct NYU Study Finds GLP-1 Medications Associated with Clinically Meaningful Benefit in Dialysis Patients

MedicalResearch.com Interview with: [caption id="attachment_71025" align="alignleft" width="225"] Dr. Weintraub[/caption] Michael A. Weintraub, MD Clinical Assistant Professor Department of Medicine NYU Grossman School of Medicine MedicalResearch.com: What is the background for this study? Response: The study addresses a critical knowledge gap in diabetes management for dialysis patients. Of the 808,000 people on dialysis in the United States, approximately 60% have diabetes and would be eligible for GLP-1 receptor agonists (GLP-1 RAs). However, these medications have not been well-studied in this population because dialysis dependence is frequently an exclusion criterion in clinical trials.